Cited by 2,077Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

Epidemiology and risk profile of heart failure

Open access
Bui, Anh L., Horwich, Tamara B., Fonarow, Gregg C.·2011·Nature Reviews Cardiology

Abstract

Heart failure (HF) is a major public health issue, with a prevalence of over 5.8 million in the USA, and over 23 million worldwide, and rising. The lifetime risk of developing HF is one in five. Although promising evidence shows that the age-adjusted incidence of HF may have plateaued, HF still carries substantial morbidity and mortality, with 5-year mortality that rival those of many cancers. HF represents a considerable burden to the health-care system, responsible for costs of more than $39 billion annually in the USA alone, and high rates of hospitalizations, readmissions, and outpatient visits. HF is not a single entity, but a clinical syndrome that may have different characteristics depending on age, sex, race or ethnicity, left ventricular ejection fraction (LVEF) status, and HF etiology. Furthermore, pathophysiological differences are observed among patients diagnosed with HF and reduced LVEF compared with HF and preserved LVEF, which are beginning to be better appreciated in epidemiological studies. A number of risk factors, such as ischemic heart disease, hypertension, smoking, obesity, and diabetes, among others, have been identified that both predict the incidence of HF as well as its severity. In this Review, we discuss key features of the epidemiology and risk profile of HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrcardio.2010.165

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MI and ischemic cardiomyopathy are among the leading causes of heart failure, associated morbidity, and death worldwide and continue to impose staggering financial burden on healthcare systems.

    “Despite advancements in clinical management, MI and ischemic cardiomyopathy are among the leading causes of heart failure, associated morbidity, and death worldwide 3,4 and continue to impose staggering financial burden on healthcare systems 3,5-8 .”

    From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [8]

    The Ischemic heart disease section calls ischemic heart disease a major risk factor for heart failure and reports that many patients develop heart failure after MI. The Introduction and Cost sections document heart failure’s worldwide prevalence, morbidity, mortality, and substantial health-care costs. They do not establish that MI and ischemic cardiomyopathy themselves are leading causes of death worldwide or quantify a financial burden specifically attributable to them; page numbers were not provided. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 144 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [30]Gordis L Epidemiology 37 84 Elsevier/Saunders Philadelphia 2009

Cited by

Sorted by citations

Authors
Bui, A. L., Horwich, T. B., & Fonarow, G. C.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Fonarow, Gregg C.
Venue
Nature Reviews Cardiology
Published
2010-11-09
Volume
8
Issue
1
Pages
30-41
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W1992644002
Cited by
2,077
References
144
Citations by year
2026: 48 · 2025: 91 · 2024: 126 · 2023: 158 · 2022: 173 · 2021: 186 · 2020: 209 · 2019: 169 · 2018: 191 · 2017: 211 · 2016: 174 · 2015: 121 · 2014: 91 · 2013: 60 · 2012: 46
FWCI
6.84
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Heart Failure Society of America
  • Ahmanson Foundation
  • National Institutes of Health (5k23hl085097-04)
  • National Heart, Lung, and Blood Institute (1K23HL085097, K23 HL085097, T32HL007895)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
heart failure, heart failure epidemiology, heart failure risk factors, heart failure prevalence, heart failure mortality, health care costs, ischemic heart disease, hypertension, smoking, obesity, diabetes mellitus
MeSH terms
Adult, Aged, Female, Heart Failure, Humans, Male, Middle Aged, Prognosis, Risk Factors, Time Factors, Incidence, Prevalence, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review